OnCo
Start here

Query the graph

Ask structured questions of the corpus: which targets have an approved ADC but no PET tracer, which cancers have no phase-3 product, which companies have products but no institutional link. Combine clauses, negate any of them, and get a linked table.

Find
where all of:
linked to a
tagged
tagged
Add clause:

Query: targets · has linked product with status Approved · has tag adc-target · no tag pet-target

Targets with an approved ADC but no PET tracer
11 targets
NamePhase / statusLinks
HER2
A growth-signal receptor. Some cancers make far too much of it, and drugs that block it or use it as a docking site have transformed those cancers.
114
MET
A receptor that is either mutated in some lung cancers or amplified as an escape route when other lung cancer drugs fail.
33
Claudin 18.2
A tight-junction protein normally hidden in the stomach lining that becomes exposed in gastric and pancreatic cancers.
27
Folate receptor alpha
Folate receptor alpha is a vitamin receptor that ovarian cancer cells carry in large numbers, used as the docking site for the ADC mirvetuximab.
20
HER3
HER3 is a cousin of HER2 that cancers use as an escape route when HER2 or EGFR are blocked.
20
Nectin-4
Nectin-4 is an adhesion protein plentiful on bladder cancer cells, used as the docking site for the ADC enfortumab vedotin.
14
CD22
CD22 is a B-cell surface protein and the docking site for the leukaemia ADC inotuzumab ozogamicin.
9
CD30
CD30 is a protein on the malignant Reed-Sternberg cells of Hodgkin lymphoma and on some T-cell lymphomas, and the address for the ADC brentuximab vedotin.
9
CD123
An interleukin receptor over-abundant on a rare aggressive blood cancer and on leukaemia stem cells.
6
CD33
CD33 is a myeloid marker and the target of the very first ADC ever approved, in 2000.
6
Tissue factor
Tissue factor is a clotting protein that cancers abnormally display on their surface, used as an ADC target in cervical cancer.
6